0354 GMT - ResMed's exemption from U.S. tariffs supports the breath-tech provider's already strong competitive position, according to Morgans analyst Derek Jellinek. He tells clients in a note that the exemption is important, but that he already liked ResMed for its expanding U.S. manufacturing footprint, the emergence of new technologies driving adoption, and favorable trends in wearables and weight-loss drugs. Jellinek observes that growth in ResMed's U.S. mask sales continues to outpace that of the broader industry, with rest-of-world sales growth poised to eventually catch up. Morgans keeps an add rating on the stock and raises its target price 1.1% to A$44.07. Shares are up 2.6% at A$37.005.(stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 27, 2025 23:54 ET (03:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.